Xbrane Biopharma AB

Kvartalsrapporter

Visar 1 grupper

  1. Kvartalsrapport Q1 2026

    ENSV
    →

    Financial Performance

    * Revenue for the quarter amounted to SEK 17.3 million (93.2), of which SEK 17.2 million (46.6) is attributable to product sales of Ximluci® and SEK 0.2 million (46.6) to licensing income. * Operating loss was SEK -10.5 million (profit 27.7). * EBITDA amounted to SEK -7.8 million (32.6). * Loss for the period was SEK -13.1 million (profit 8.2). *…

    Öppna rapport